SigVie-002 · Sigvotatug Vedotin

Design - Phase 3, randomized, open-label trial (NCT06012435, Be6A Lung-01) of sigvotatug vedotin - an integrin beta-6 (IB6)-directed antibody-drug conjugate - versus docetaxel in previously treated locally advanced/metastatic non-squamous NSCLC (>=1 prior line). Sponsor: Seagen/Pfizer; page reports n=703.

Overall survival (primary - not met) - Sigvotatug vedotin did not show a statistically significant improvement in overall survival versus docetaxel in the overall population (Pfizer topline, June 22, 2026). Discrete OS/PFS values have not yet been released; detailed results to follow at a future congress.

Subgroup signal (one prior line) - Among patients with only one prior line of systemic therapy (~2/3 of patients), Pfizer reported a numerically stronger OS and PFS trend for sigvotatug vedotin. These are sponsor-reported subgroup observations; no statistical conclusion was claimed.

Safety / biomarker - Safety was manageable and consistent with prior studies. In an exploratory analysis, no clear relationship between IB6 expression level and clinical response was observed, despite IB6 expression in ~90% of NSCLC tumors.

Regulatory / next steps - Investigational - not FDA approved. Pfizer cited the one-prior-line trend as rationale for continued evaluation in earlier lines, including the Phase 3 Be6A Lung-02 study of sigvotatug vedotin plus pembrolizumab in first-line NSCLC (PD-L1 TPS >=50%).

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated August 19, 2026.

Overall Survival (primary)

In the overall population, sigvotatug vedotin did not show a statistically significant improvement in overall survival (OS) compared with docetaxel in patients with previously treated locally advanced/metastatic non-squamous NSCLC (≥1 prior line). (Pfizer topline, Jun 22 2026 — discrete OS/PFS values not yet released; detailed results to follow at a future congress.)

Subgroup signal — one prior line (~2/3 of patients)

Pfizer reported that among patients who had received only one prior line of systemic therapy, a numerically stronger trend for OS and PFS was observed for sigvotatug vedotin versus docetaxel. The company stated this as its rationale for ongoing evaluation in earlier lines, including the Phase 3 Be6A Lung-02 study of sigvotatug vedotin plus pembrolizumab in first-line NSCLC (PD-L1 TPS ≥50%). These are sponsor-reported observations from a subgroup; no statistical conclusion was claimed.

Safety & biomarker

Safety was manageable and consistent with prior studies. In an exploratory analysis, no clear relationship between IB6 expression level and clinical response was observed, despite IB6 expression in ~90% of NSCLC tumors.

"Although the study did not meet its overall survival endpoint, in second-line patients the data suggest a clinically meaningful survival benefit for sigvotatug vedotin over docetaxel, supporting continued scientific evaluation of sigvotatug vedotin in earlier lines in combination with immunotherapy."

"This observed clinical benefit, along with our Phase 1 combination data in the first-line setting, reinforces our confidence in the potential of the sigvotatug vedotin program, including an ongoing Phase 3 trial in combination with pembrolizumab in first-line advanced NSCLC."

What is the SigVie-002 trial?

SigVie-002 (NCT06012435, also called Be6A Lung-01) is a Phase 3, randomized, open-label study comparing sigvotatug vedotin - an antibody-drug conjugate directed at integrin beta-6 (IB6) - against docetaxel in patients with previously treated locally advanced or metastatic non-squamous non-small cell lung cancer. The sponsor is Seagen, a wholly owned subsidiary of Pfizer.

What did SigVie-002 show?

The trial did not meet its primary endpoint: sigvotatug vedotin did not show a statistically significant improvement in overall survival versus docetaxel in the overall population, per Pfizer's topline announcement of June 22, 2026. Among patients who had received only one prior line of therapy (~2/3 of the study), a numerically stronger OS and PFS trend was observed, though no statistical conclusion was claimed. Detailed results are expected at a future congress.

Is sigvotatug vedotin FDA approved?

No. Sigvotatug vedotin is an investigational agent and is not FDA approved. Despite the missed primary endpoint in SigVie-002, Pfizer is continuing development in earlier treatment lines, including the Phase 3 Be6A Lung-02 trial combining sigvotatug vedotin with pembrolizumab in first-line NSCLC with PD-L1 TPS >=50%.

What is the safety profile of sigvotatug vedotin in SigVie-002?

Per the sponsor's topline announcement, safety was manageable and consistent with prior studies of sigvotatug vedotin. Detailed safety data had not been released at the time of the topline readout and are expected with the full results at a future congress.

Why is SigVie-002 important?

It is a notable Phase 3 readout in the crowded post-immunotherapy NSCLC ADC landscape: a negative primary OS result in the overall 2L+ population, but with a sponsor-reported signal in one-prior-line patients that redirects the program toward earlier lines. The exploratory finding of no clear IB6 expression-response relationship - despite ~90% of NSCLC tumors expressing IB6 - also informs biomarker strategy for the ADC class.